Strong Revenue Growth
Syndax reported $45.9 million in total revenue for the third quarter, representing a strong 21% growth over the prior quarter.
Revuforj and Niktimvo Launch Success
Revuforj net revenue was $32 million in Q3, up 12% from the prior quarter. Niktimvo reported a 27% increase in net revenue over the prior quarter, with annualizing sales nearly reaching $200 million.
FDA Approval for Revuforj
Revuforj received FDA approval for relapsed/refractory NPM1 mutated AML, tripling the addressable patient population.
Positive Clinical Data
Real-world data from Moffitt Cancer Center showed 79% overall response rate for Revuforj, with significant MRD negativity.